306 related articles for article (PubMed ID: 25175462)
1. Synergistic antitumor effect of ginsenoside Rg3 and cisplatin in cisplatin‑resistant bladder tumor cell line.
Lee YJ; Lee S; Ho JN; Byun SS; Hong SK; Lee SE; Lee E
Oncol Rep; 2014 Nov; 32(5):1803-8. PubMed ID: 25175462
[TBL] [Abstract][Full Text] [Related]
2. Multikinase inhibitor motesanib enhances the antitumor effect of cisplatin in cisplatin‑resistant human bladder cancer cells via apoptosis and the PI3K/Akt pathway.
Ho JN; Byun SS; Lee SE; Youn JI; Lee S
Oncol Rep; 2019 Apr; 41(4):2482-2490. PubMed ID: 30816494
[TBL] [Abstract][Full Text] [Related]
3. Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-kappaB.
Kim SM; Lee SY; Cho JS; Son SM; Choi SS; Yun YP; Yoo HS; Yoon DY; Oh KW; Han SB; Hong JT
Eur J Pharmacol; 2010 Apr; 631(1-3):1-9. PubMed ID: 20056115
[TBL] [Abstract][Full Text] [Related]
4. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
Lu M; Fei Z; Zhang G
Biomed Pharmacother; 2018 Jan; 97():1282-1288. PubMed ID: 29156516
[TBL] [Abstract][Full Text] [Related]
5. [Inducement effect of ginsenoside Rg3 on apoptosis of human bladder transitional cell carcinoma cell line EJ].
Chen JX; Peng HM; Pu SP; Guo YP
Zhongguo Zhong Yao Za Zhi; 2007 Aug; 32(16):1680-4. PubMed ID: 18027667
[TBL] [Abstract][Full Text] [Related]
6. Synergistic antitumor effect of triptolide and cisplatin in cisplatin resistant human bladder cancer cells.
Ho JN; Byun SS; Lee S; Oh JJ; Hong SK; Lee SE; Yeon JS
J Urol; 2015 Mar; 193(3):1016-22. PubMed ID: 25229559
[TBL] [Abstract][Full Text] [Related]
7. Suberoylanilide Hydroxamic Acid Can Re-sensitize a Cisplatin-Resistant Human Bladder Cancer.
Ryu H; Jin H; Ho JN; Bae J; Lee E; Lee SE; Lee S
Biol Pharm Bull; 2019; 42(1):66-72. PubMed ID: 30606990
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects of ginsenoside Rg3 on human hepatocellular carcinoma cells.
Zhang C; Liu L; Yu Y; Chen B; Tang C; Li X
Mol Med Rep; 2012 May; 5(5):1295-8. PubMed ID: 22366885
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of NF-kappaB by ginsenoside Rg3 enhances the susceptibility of colon cancer cells to docetaxel.
Kim SM; Lee SY; Yuk DY; Moon DC; Choi SS; Kim Y; Han SB; Oh KW; Hong JT
Arch Pharm Res; 2009 May; 32(5):755-65. PubMed ID: 19471891
[TBL] [Abstract][Full Text] [Related]
10. Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-κB signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer.
Yuan Z; Jiang H; Zhu X; Liu X; Li J
Biomed Pharmacother; 2017 May; 89():227-232. PubMed ID: 28231544
[TBL] [Abstract][Full Text] [Related]
11. [Effect of ginsenoside Rg3 on Pim-3 and Bad proteins in human pancreatic cancer cell line PANC-1].
Jian J; Hu ZF; Huang Y
Ai Zheng; 2009 May; 28(5):461-5. PubMed ID: 19624871
[TBL] [Abstract][Full Text] [Related]
12. Ginsenoside Rg3 inhibit hepatocellular carcinoma growth via intrinsic apoptotic pathway.
Jiang JW; Chen XM; Chen XH; Zheng SS
World J Gastroenterol; 2011 Aug; 17(31):3605-13. PubMed ID: 21987607
[TBL] [Abstract][Full Text] [Related]
13. Induction of G2/M phase cell cycle arrest and apoptosis by ginsenoside Rf in human osteosarcoma MG‑63 cells through the mitochondrial pathway.
Shangguan WJ; Li H; Zhang YH
Oncol Rep; 2014 Jan; 31(1):305-13. PubMed ID: 24173574
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of multiple myeloma cell proliferation by ginsenoside Rg3 via reduction in the secretion of IGF-1.
Li Y; Yang T; Li J; Hao HL; Wang SY; Yang J; Luo JM
Mol Med Rep; 2016 Sep; 14(3):2222-30. PubMed ID: 27430248
[TBL] [Abstract][Full Text] [Related]
15. 20(S)-ginsenoside Rg3 promotes senescence and apoptosis in gallbladder cancer cells via the p53 pathway.
Zhang F; Li M; Wu X; Hu Y; Cao Y; Wang X; Xiang S; Li H; Jiang L; Tan Z; Lu W; Weng H; Shu Y; Gong W; Wang X; Zhang Y; Shi W; Dong P; Gu J; Liu Y
Drug Des Devel Ther; 2015; 9():3969-87. PubMed ID: 26309394
[TBL] [Abstract][Full Text] [Related]
16. Ginsenoside Rg3 sensitizes hypoxic lung cancer cells to cisplatin via blocking of NF-κB mediated epithelial-mesenchymal transition and stemness.
Wang J; Tian L; Khan MN; Zhang L; Chen Q; Zhao Y; Yan Q; Fu L; Liu J
Cancer Lett; 2018 Feb; 415():73-85. PubMed ID: 29199005
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment with the γ-secretase inhibitor DAPT sensitizes drug-resistant ovarian cancer cells to cisplatin by downregulation of Notch signaling.
Wang M; Ma X; Wang J; Wang L; Wang Y
Int J Oncol; 2014 Apr; 44(4):1401-9. PubMed ID: 24535252
[TBL] [Abstract][Full Text] [Related]
18. Ginsenoside Rg3 Combined with Oxaliplatin Inhibits the Proliferation and Promotes Apoptosis of Hepatocellular Carcinoma Cells via Downregulating PCNA and Cyclin D1.
Shan K; Wang Y; Hua H; Qin S; Yang A; Shao J
Biol Pharm Bull; 2019 Jun; 42(6):900-905. PubMed ID: 30930425
[TBL] [Abstract][Full Text] [Related]
19. Ginsenoside Rg3 suppresses the growth of gemcitabine-resistant pancreatic cancer cells by upregulating lncRNA-CASC2 and activating PTEN signaling.
Zou J; Su H; Zou C; Liang X; Fei Z
J Biochem Mol Toxicol; 2020 Jun; 34(6):e22480. PubMed ID: 32104955
[TBL] [Abstract][Full Text] [Related]
20. VEGF-C inhibition reverses resistance of bladder cancer cells to cisplatin via upregulating maspin.
Zhu H; Yun F; Shi X; Wang D
Mol Med Rep; 2015 Aug; 12(2):3163-9. PubMed ID: 25936422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
